Straits Times Index
3,230.55 +21.37 (+0.67%) Nikkei
26,781.68 +176.84 (+0.66%) Hang Seng
20,697.36 +581.16 (+2.89%) FTSE 100
7,585.46 +20.54 (+0.27%) BTC-USD
28,786.56 -204.26 (-0.70%) CMC Crypto 200
625.79 -3.71 (-0.59%)
Roche Holding AG (ROG.SW)
| Previous close | 333.00 |
| Open | 333.00 |
| Bid | 0.00 x 0 |
| Ask | 329.85 x 0 |
| Day's range | 327.85 - 333.40 |
| 52-week range | 308.75 - 404.20 |
| Volume | |
| Avg. volume | 1,530,142 |
| Market cap | 288.834B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 20.36 |
| EPS (TTM) | 16.20 |
| Earnings date | 21 Jul 2022 |
| Forward dividend & yield | 9.30 (2.79%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | 384.09 |
- Zacks
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
- Business Wire
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
SOUTH SAN FRANCISCO, Calif., May 26, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Congress from June 9-12. Data from the Phase II NP30179 expansion study demonstrated that, afte
- Zacks
Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL
Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.
